An emergency summit to discuss how to safeguard the clinical research industry in the U.K. before and after Brexit will take place on April 5.
An emergency summit to discuss how to safeguard the clinical research industry in the U.K. before and after Brexit-the planned exit of the U.K. from the European Union (EU)-will take place on Wednesday, April 5th at a venue in the South Bucks/Berkshire area.
“Pressure is mounting on the government because the issue is very real. The clinical research industry is already experiencing a challenging time with the ongoing talent crisis. It’s important we proactively manage the transition through Brexit to avoid long-term issues to the industry,” says Jacqueline Johnson North, CEO of IAOCR, the accrediting organization for the international clinical research industry. “We can’t wait for the Government to make decisions. By working together, we will have a stronger voice in Parliament.”
The clinical research sector is of great value to the U.K. economy, and many CROs and pharmaceutical companies have established their European headquarters in the country, she continued. Globally there is also a talent crisis, which means the U.K. needs to attract and retain talent, both now and in the future, and the implications of Brexit must be considered and proactively managed.
Clinical research staff and the companies employing them are operating in times of uncertainty, according to Johnson North. The current position of the U.K. government is that it is unwilling to guarantee the rights of EU nationals from other countries to remain in the country, until the rights of U.K. nationals living in the EU have been secured.
The initial meeting will focus on protecting the current and future talent of the industry, as well as defining other key issues that the industry needs to consider as the UK prepares to exit the EU. It will create a taskforce to develop a practical, strategic positioning paper with clear messages on what the clinical research industry needs to survive and thrive pre- and post-Brexit.
“We have had a lot of interest in the summit and we will be reviewing all interested parties next week,” noted Jane Gulmez, Global Client Communications Manager of IAOCR.
For more details about the event, contact her on +44 (0) 1628 565 544 or by email at jgulmez@iaocr.com.
Philip Ward is the European Editor for Applied Clinical Trials
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.